Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Dutasteride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dutasteride works in treating patients with recurrent prostate cancer that did not respond to androgen-deprivation therapy.

Key facts

Study ID

NCT00403000

Run by

Roswell Park Cancer Institute

People needed

27

Starts

2004-12-01

Expected to finish

2013-04-01

Last updated by the study team

2013-05-01

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Roswell Park Cancer Institute — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.